Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Circulation

• Publication date

  2000-11-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.102.22.2720PMID 11094038
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Altered hemostasis in pulmonary hypertension.

  1998cited by this paper
• Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

  1998cited by this paper
• Increased levels of soluble P-selectin in hypercholesterolemic patients.

  1998cited by this paper
• Primary pulmonary hypertension.

  1997cited by this paper
• Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension.

  1997cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996cited by this paper
• Plasma levels of thrombomodulin in pulmonary hypertension.

  1996cited by this paper
• Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension.

  1996cited by this paper
• Pharmacodynamic profile of prostacyclin.

  1995cited by this paper
• Soluble form of P-selectin in plasma is elevated in acute lung injury.

  1995cited by this paper
• P-selectin induces the expression of tissue factor on monocytes.

  1994cited by this paper
• Levels of plasma thrombomodulin are increased in atheromatous arterial disease.

  1993cited by this paper
• Soluble P‐selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome

  1993cited by this paper
• The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

  1992cited by this paper
• Characterization of GMP-140 (P-selectin) as a circulating plasma protein

  1992cited by this paper
• Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level.

  1991cited by this paper
• One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies.

  1990cited by this paper
• PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY

  1987influential reference
• Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects.

  1987cited by this paper
• A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation

  1985cited by this paper
• Primary pulmonary hypertension: natural history and the importance of thrombosis.

  1984cited by this paper
• Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.

  1981cited by this paper
• Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases

  1970cited by this paper
• The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects

  1958cited by this paper

• Transcriptional signatures of endothelial cells shape immune responses in cardiopulmonary health and disease

  2025cites this paper
• DIAGNÓSTICO

  2025cites this paper
• Pulmonary Vascular Remodeling in Pulmonary Hypertension

  2023cites this paper
• A very rare cause of pre‐capillary pulmonary hypertension: The PAMI syndrome

  2023cites this paper
• Platelet Activation Markers in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease

  2022cites this paper
• Nets, pulmonary arterial hypertension, and thrombo-inflammation

  2022cites this paper
• The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling

  2022cites this paper
• Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

  2021cites this paper
• Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension

  2021cites this paper
• Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale

  2021cites this paper
• Endothelial cells in the pathogenesis of pulmonary arterial hypertension

  2021cites this paper
• Approaches to treat pulmonary arterial hypertension by targeting bmpr2 - from cell membrane to nucleus.

  2021cites this paper
• Inflammation in Pulmonary Arterial Hypertension.

  2021cites this paper
• International Journal of Medical Science and Current Research (IJMSCR)

  2021cites this paper
• Evidence of Accumulated Endothelial Progenitor Cells in the Lungs of Rats with Pulmonary Arterial Hypertension by 89Zr-oxine PET Imaging

  2020cites this paper
• Beyond Thrombosis: the Role of Platelets in Pulmonary Hypertension

  2020cites this paper
• Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19

  2020cites this paper
• Perivascular Inflammation in Pulmonary Arterial Hypertension

  2020cites this paper
• The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers

  2020cites this paper
• AOS ameliorates monocrotaline-induced pulmonary hypertension by restraining the activation of P-selectin/p38MAPK/NF-κB pathway in rats.

  2019cites this paper
• The endothelial status reflected by circulating endothelial cells, circulating endothelial progenitor cells and soluble thrombomodulin in patients with mild and resistant hypertension.

  2019cites this paper
• Prodrug approaches to reduce treprostinil toxicity

  2019cites this paper
• Dynamics of Soluble Thrombomodulin and Circulating miRNAs in Patients with Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation

  2019cites this paper
• Association between MDR1 gene polymorphism and clinical course of pediatric pulmonary arterial hypertension

  2018cites this paper
• Platelet activation markers in children with congenital heart disease associated with pulmonary arterial hypertension

  2018cites this paper
• Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series)

  2018cites this paper
• Biomarkers in Pulmonary Hypertension.

  2018cites this paper
• Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension.

  2018cites this paper
• The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series)

  2017influential citation
• The effects of corrective surgery on endothelial biomarkers and anthropometric data in children with congenital heart disease

  2017cites this paper
• Psgl-1/p-selectin interaction: Regulation of immune and vascular homeostasis

  2017cites this paper
• Soluble P-selectin is the smoke, not the fire.

  2017cites this paper
• Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil

  2017cites this paper
• Factors influencing outcomes in patients with Eisenmenger syndrome: a nine-year follow-up study

  2017cites this paper
• Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.

  2016cites this paper
• Adhesion Molecules: Master Controllers of the Circulatory System.

  2016cites this paper
• Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension.

  2016cites this paper
• Relevance of Angiopoietin-2 and Soluble P-Selectin Levels in Patients with Pulmonary Arterial Hypertension Receiving Combination Therapy with Oral Treprostinil: A FREEDOM-C2 Biomarker Substudy

  2016influential citation
• Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.

  2016cites this paper
• Enhanced platelet activity in atrial septal defect

  2016cites this paper
• Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension.

  2015cites this paper
• The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors.

  2015cites this paper
• HIV Protease Inhibitors in Pulmonary Hypertension: Rationale and Design of a Pilot Trial in Idiopathic Pulmonary Arterial Hypertension

  2015cites this paper
• Platelet hyperactivity in thalassemia patients with elevated tricuspid regurgitant velocity and the association with hemolysis.

  2015cites this paper
• Prognostic value of neutrophil-to-lymphocyte ratio in pulmonary arterial hypertension

  2015cites this paper
• Adjunct Therapy and Calcium Channel Blockers

  2015cites this paper
• Thrombosis, platelets, microparticles and PAH: more than a clot.

  2014cites this paper
• Update in systemic sclerosis-associated pulmonary arterial hypertension.

  2014cites this paper
• Inflammation in pulmonary arterial hypertension: is it time to quell the fire?

  2014cites this paper
• Mean platelet volume levels predict pulmonary artery hypertension in patients with atrial septal defect.

  2014cites this paper
• Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension

  2014cites this paper
• MARKERS OF SYSTEMIC INFLAMMATION AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  2014cites this paper
• Mean platelet volume levels predict pulmonary artery hypertension in patients with atrial septal defect

  2014cites this paper
• Platelet-Derived Microparticles and Platelet Function Profile in Children With Congenital Heart Disease

  2013cites this paper
• Inflammatory Markers Are Elevated in Eisenmenger Syndrome

  2013cites this paper
• Dose-dependent association of smoking and bronchial hyperresponsiveness

  2013cites this paper
• Standard nonspecific therapies in the management of pulmonary arterial hypertension.

  2013cites this paper
• Immune and inflammatory mechanisms in pulmonary arterial hypertension.

  2012cites this paper
• Innovation thérapeutique dans la dysfonction endothéliale associée à l'hypertension artérielle pulmonaire

  2012cites this paper
• MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension: Results of a Network Bioinformatics Approach

  2012cites this paper
• Exploration of the antiplatelet activity profile of betulinic acid on human platelets.

  2012cites this paper
• Thrombin and Platelets in Pulmonary Hypertension: A Lot More Than Clot

  2012cites this paper
• Characterising lymphocyte subpopulations and heat shock protein 70 expression in clinical and experimental pulmonary arterial hypertension

  2012cites this paper
• Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.

  2012cites this paper
• Platelets in Pulmonary Hypertension: a Causative Role or a Simple Association?

  2012cites this paper
• Platelets in pulmonary vascular physiology and pathology

  2012cites this paper
• Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT

  2011cites this paper
• Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT.

  2011cites this paper
• Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease.

  2011cites this paper
• Key role of the RhoA/Rho kinase system in pulmonary hypertension.

  2011cites this paper
• Inflammatory mechanisms in the pathogenesis of pulmonary arterial hypertension.

  2011cites this paper
• Prostacyclins , Endothelin Inhibitors , and Phosphodiesterase-5 Inhibitors in Pulmonary Hypertension

  2011cites this paper
• Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension

  2011cites this paper
• Estudo de marcadores de disfunção endotelial e de inflamação em portadores de hipertensão arterial pulmonar: implicações terapêuticas e prognósticas

  2011cites this paper
• Platelet Indices in Patients With Pulmonary Arterial Hypertension

  2011cites this paper
• A Randomized Clinical Trial Of Aspirin And Simvastatin For Pulmonary Arterial Hypertension: ASA-STAT

  2011cites this paper
• Systemic Evaluation of Platelet and Leukocyte Activation and Interaction in a Rat Model of Pulmonary Arterial Hypertension

  2010cites this paper
• Comparison of Endothelial Biomarkers According to Reversibility of Pulmonary Hypertension Secondary to Congenital Heart Disease

  2010cites this paper
• Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension.

  2010cites this paper
• Enhanced hemostatic indices in patients with pulmonary arterial hypertension: an observational study.

  2010cites this paper
• Pulmonary arterial hypertension and lung transplantation.

  2010cites this paper
• Pulmonary Arterial Hypertension and Lung Transplantation

  2010cites this paper
• Recherche d'une hypercoagulabilité au cours de l'hypertension artérielle pulmonaire

  2010cites this paper
• Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.

  2009cites this paper
• Increased P-selectin expression on platelets and decreased plasma thrombomodulin in Fontan patients.

  2009cites this paper
• Inflammation, growth factors, and pulmonary vascular remodeling.

  2009cites this paper
• Antikoagulation bei pulmonaler arterieller Hypertonie

  2009cites this paper
• Heme oxygenase-2 and large-conductance Ca2+-activated K+ channels: lung vascular effects of hypoxia.

  2009cites this paper
• Avaliação do comprometimento da função do endotélio em pacientes com hipertensão arterial pulmonar idiopática e em esquistossomóticos

  2009cites this paper
• Raised LIGHT levels in pulmonary arterial hypertension: potential role in thrombus formation.

  2008cites this paper
• Differential involvement of cyclooxygenase isoforms in neutrophil migration in vivo and in vitro.

  2008cites this paper
• Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study

  2008cites this paper
• Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study.

  2008cites this paper
• Epoprostenol infusion therapy changes angiographic findings of pulmonary arteries in patients with idiopathic pulmonary arterial hypertension.

  2008cites this paper
• Antikoagulation bei pulmonal arterieller Hypertonie

  2008cites this paper
• Prostacyclin Therapy for Pulmonary Arterial Hypertension

  2008cites this paper
• Plasma level of soluble P-selectin in patients with rheumatic mitral stenosis and sinus rhythm undergoing percutaneous mitral balloon valvuloplasty

  2007cites this paper
• Standard therapies for pulmonary arterial hypertension.

  2007cites this paper
• VASCULARENDOTHELIALGROWTHFACTOR, LIPOPOROTEIN-ASSOCIATED PHOSPHOLIPASEA2, SP-SELECTINANDANTIPHOSPHOLIPIDANTIBODIES, BIOLOGICALMARKERSWITHPROGNOSTICVALUEINPULMONARY HYPERTENSIONASSOCIATEDWITHCHRONICOBSTRUCTIVEPULMONARY DISEASEANDSYSTEMICLUPUSERITHEMATOSUS

  2007cites this paper
• Prostanoid therapy for pulmonary arterial hypertension.

  2007cites this paper